Voleon Capital Management LP Purchases Shares of 7,884 Thermo Fisher Scientific Inc. $TMO

Key Points

• Voleon Capital Management LP has acquired a new position in Thermo Fisher Scientific Inc., purchasing 7,884 shares valued at approximately $3.9 million during Q1.
• Multiple institutional investors increased their stakes in Thermo Fisher, with ownership by institutional investors now at 89.23%.
• Thermo Fisher recently reported earnings exceeding estimates, with an EPS of $5.36 for the quarter, and announced a quarterly dividend of $0.43 to be paid in October.

Voleon Capital Management LP acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 7,884 shares of the medical research company's stock, valued at approximately $3,923,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares during the last quarter. Port Capital LLC lifted its position in shares of Thermo Fisher Scientific by 1.6% in the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock valued at $721,000 after buying an additional 22 shares during the last quarter. Monograph Wealth Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock valued at $4,507,000 after buying an additional 23 shares during the last quarter. Intergy Private Wealth LLC lifted its position in shares of Thermo Fisher Scientific by 5.8% in the first quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after buying an additional 23 shares during the last quarter. Finally, Root Financial Partners LLC lifted its position in shares of Thermo Fisher Scientific by 5.0% in the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock valued at $252,000 after buying an additional 24 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,066 shares of company stock valued at $14,182,963. Corporate insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TMO. Barclays raised their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Raymond James Financial reiterated an "outperform" rating and set a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. Evercore ISI lowered their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $589.38.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded down $5.38 during trading hours on Wednesday, reaching $477.03. The company's stock had a trading volume of 1,442,085 shares, compared to its average volume of 1,608,466. The firm's 50 day simple moving average is $464.58 and its 200-day simple moving average is $452.37. The company has a market capitalization of $180.13 billion, a price-to-earnings ratio of 27.59, a PEG ratio of 2.58 and a beta of 0.75. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.